Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment | Zendy

Mamoudou Maïga | Zendy; Nicole C. Ammerman | Zendy; Mariama C. Maiga | Zendy; Anatole Tounkara | Zendy; Sophia Siddiqui | Zendy; Michael A. Polis | Zendy; Robert L. Murphy | Zendy; William R. Bishai | Zendy

Open Access

Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment

Author(s) -

Mamoudou Maïga,

Nicole C. Ammerman,

Mariama C. Maiga,

Anatole Tounkara,

Sophia Siddiqui,

Michael A. Polis,

Robert L. Murphy,

William R. Bishai

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit187

Subject(s) - tuberculosis , phosphodiesterase , medicine , adjuvant , pharmacology , duration (music) , pharmacotherapy , adjuvant therapy , immunology , chemotherapy , biology , enzyme , pathology , biochemistry , art , literature

Shortening tuberculosis treatment could significantly improve patient adherence and decrease the development of drug resistance. Phosphodiesterase inhibitors (PDE-Is) have been shown to be beneficial in animal models of tuberculosis. We assessed the impact of PDE-Is on the duration of treatment in tuberculous mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research